Cannabinoids in dogs: what the science says

Research date: 2026-11-05. Peer-reviewed veterinary papers wherever they exist; rodent and human data are labeled as such. "No canine data" is stated where that is the case. Weight conversions used: 15 lb = 6.8 kg, 40 lb = 18.1 kg, 90 lb = 40.8 kg.

The five findings that drive the formulation

CBDA beats CBD on absorption in dogs, by a lot. At the same 1 mg/kg dose, CBDA reaches 2 to 4 times the blood level of CBD (Cornell 2025 isolate study: 236 vs 70 ng/mL; Wakshlag 2020 soft chew: 510 vs 226 ng/mL). CBDA is also cleared by a different liver pathway (glucuronidation, not CYP), which matters for drug interactions.
CBD:CBDA 1:1 is the only ratio with real canine efficacy trials. Two positive placebo-controlled trials (Gamble 2018 osteoarthritis, Loewinger 2022 itch) and one negative (post-surgical pain). All funded by ElleVet, no independent replication yet, but nothing else comes close.
Neutral CBG is almost inert in dogs. 2 mg/kg twice daily for two weeks produced 5 ng/mL in serum; the acid form CBGA reached 250 ng/mL, about 40 times more (Amstutz 2022). If CBG goes in a chew, it has to be CBGA. Even then, no canine efficacy trial exists.
CBN has no canine data. No pharmacokinetics, no efficacy, no safety study in dogs. Sleep data are rats and mixed human trials. CBN is a weak CB1 agonist (about 10% of THC) in a species with dense CB1 receptors. It is a marketing ingredient today.
Full-spectrum did not improve absorption over isolates in the Cornell 2025 head-to-head. The measurable advantage of hemp extracts is their CBDA content, not an "entourage" of minors. Broad-spectrum with non-detect THC is the right choice for labeling and safety, not for a synergy claim.

Summary per cannabinoid

Cannabinoid	Canine absorption	Canine efficacy by use	Safe range in dogs	Verdict for a chew
CBD	Low bioavailability (under 20–31%). Oil 2 mg/kg: Cmax about 145 ng/mL, Tmax 1.5–2 h, half-life about 4 h. Accumulates with daily dosing.	Arthritis/mobility: B (3 positive RCTs, 2 negative). Anxiety/stress: B minus (Mars-funded single-dose and 6-month positives; UK fireworks and Italian shelter negatives). Seizures as adjunct: B. Itch: B minus. GI, appetite, cognition: none.	1–4 mg/kg/day well tolerated for 6–9 months. ALP (a liver enzyme) rises in over half of dogs at 4 mg/kg/day and above, bone-isoform driven, not damage.	The workhorse. Studied doses are 2–5 mg/kg/day.
CBDA	2–4 times CBD's exposure at equal dose. Soft chew at about 1 mg/kg: Cmax 510 ng/mL. Lecithin and sesame oil gave the best two-week retention.	Only tested as 1:1 with CBD: arthritis B, itch B minus, post-op pain negative.	1 mg/kg twice daily for 90 days with CBGA: no ALP rise, minor GI signs (Koll 2026).	Highest-value ingredient per mg. Needs cold processing.
CBG / CBGA	Neutral CBG barely absorbed; CBGA about 40 times better.	No canine efficacy data. Mouse colitis and one small human anxiety study only.	2 mg/kg twice daily for 2 weeks and 1 mg/kg CBGA twice daily for 90 days: no adverse events.	Use CBGA if at all; still unproven.
CBN	No canine data.	No canine data. Rat sleep study positive; human 20 mg reduced night awakenings in one trial and failed in a 2026 insomnia RCT.	No canine safety data.	Marketing-grade for dogs.
CBC	No canine PK; CBCA appeared as a trace analyte in Koll 2026.	No canine data. Mouse gut studies only.	None.	Marketing-grade.
Terpenes (linalool, myrcene, caryophyllene)	No canine data.	No canine data. Mouse-level only.	Linalool/lavender toxic to dogs at high ingested amounts.	Flavor-level only; no claims.

Grade key: A = two or more adequately powered placebo-controlled canine trials agreeing; B = at least one canine placebo-controlled trial, small or with conflicting trials; C = uncontrolled canine or rodent/human only.

By line

Chill

Study	Finding	Dose
Hunt 2023 (Waltham) RCT	4 mg/kg CBD two hours before separation or a car ride: dogs rated less stressed, lower cortisol in one paradigm	4 mg/kg once
Flint 2024 (Waltham) 6-month RCT	4 mg/kg/day THC-free CBD: lower cortisol at weeks 0, 8, 16, not 24; fewer stress behaviors; effect faded as placebo dogs habituated	4 mg/kg/day
Flint 2025 crossover, n=54	2 and 4 mg/kg CBD alone did nothing; 2 mg/kg CBD plus L-tryptophan plus alpha-casozepine blunted the cortisol rise (p=0.016), "mild"	2 mg/kg + co-actives
Morris 2020 fireworks model	1.4 mg/kg/day for a week: no effect; trazodone worked, CBD did not	negative
Marliani 2024 shelter dogs	No behavioral difference; hair cortisol rose in the CBD group	negative

What this supports: situational use at about 4 mg/kg two hours before the stressor, or daily use with a fading effect. Low daily doses failed. The one canine trial of a CBD-plus-botanical blend used alpha-casozepine and tryptophan, not chamomile or L-theanine.

Mobility

Study	Finding	Dose
Gamble 2018 (Cornell) crossover, n=16	2 mg/kg CBD/CBDA 1:1 oil twice daily for 4 weeks: owner and vet pain scores improved; ALP rose	2 mg/kg q12h
Verrico 2020 RCT, n=20	20 mg/day (0.5 mg/kg) and 50 mg/day isolate: dose-dependent improvement; liposomal 20 mg matched naked 50 mg	0.5–1.2 mg/kg/day
Talsma 2024 (CSU) crossover, n=39	5 mg/kg broad-spectrum twice daily for 45 days: vet and owner scores improved; ALP rose more with an NSAID; about 10% GI signs	5 mg/kg q12h
Mejia 2021 (CSU) crossover, n=23	2.5 mg/kg full-spectrum twice daily for 6 weeks: no difference from placebo	negative
Klatzkow 2023 post-TPLO, n=44	2–2.5 mg/kg CBD/CBDA twice daily: no benefit on acute surgical pain	negative

What this supports: chronic arthritis, not acute pain. Positive trials run from 0.5 mg/kg/day isolate to 10 mg/kg/day broad-spectrum; the most-cited protocol is 2 mg/kg twice daily of 1:1 CBD/CBDA.

Daily

Long-term tolerability is the evidence base, not efficacy: 4 mg/kg/day for 6 months (Bradley 2022) and 5 mg/kg/day for 36 weeks (Corsato Alvarenga 2024) were well tolerated with ALP elevation; 1 mg/kg CBDA plus 1 mg/kg CBGA twice daily for 90 days showed no ALP rise (Koll 2026). Itch: 2 mg/kg CBD/CBDA reduced pruritus (Loewinger 2022). Nothing in dogs for GI, appetite, cognition or immune function.

Dose translation against 5 / 10 / 20 mg chews

Study dose	15 lb	40 lb	90 lb	Used as
0.5 mg/kg/day	3.4 mg	9 mg	20 mg	Verrico low arm, once daily, positive
1 mg/kg	7 mg	18 mg	41 mg	Cornell PK; Koll CBDA/CBGA twice daily
2 mg/kg	14 mg	36 mg	82 mg	Gamble, Loewinger, twice daily
4 mg/kg	27 mg	72 mg	163 mg	Hunt single dose; Bradley, Flint once daily

A 15 lb dog on one 5 mg chew is at 0.7 mg/kg; on a 10 mg chew, 1.5 mg/kg. Fine.
A 40 lb dog on one 20 mg chew is at 1.1 mg/kg, inside Verrico's positive range for arthritis, below every other protocol.
A 90 lb dog on one 20 mg chew is at 0.5 mg/kg, the floor. At Gamble's dose it would need eight 20 mg chews a day.
CBDA is the lever. Because 1 mg CBDA gives roughly 2–3.5 mg CBD's worth of blood exposure, a 10 mg CBD + 10 mg CBDA chew behaves more like a 30–40 mg CBD chew on blood levels, at the same ingredient weight. No trial proves exposure equals efficacy per mg, but Gamble and Loewinger used exactly this 1:1 mix.

Ratios and combinations

Combination	Canine evidence	Verdict
CBD:CBDA 1:1	PK in two studies; two positive efficacy RCTs; one negative	Best-supported ratio in dogs
CBD + CBG	PK only; neutral CBG inert; CBGA absorbed and safe for 90 days	Marketing until a trial exists; use CBGA if used
CBD + CBN	Nothing in dogs	Marketing; adds a weak CB1 agonist
CBD + CBC	Nothing in dogs	Marketing
Broad-spectrum vs isolate	No absorption advantage (Cornell 2025); both forms showed arthritis effects in separate trials	Choose broad-spectrum for THC-free labeling and CBDA, not for synergy
CBD + alpha-casozepine + tryptophan	One canine crossover (n=54): blunted cortisol where CBD alone did not	The only blend with canine data

Safety notes for the label and the vet conversation

ALP elevation is expected at 2 mg/kg twice daily and above; it tracks the bone isoform, not liver damage, but should be disclosed and monitored. NSAID co-use raises it further.
Common adverse events: soft stool, vomiting, reduced appetite at higher doses; sedation and ataxia at seizure-trial doses.
CBD and CBDA inhibit canine tramadol metabolism in vitro; no effect on the midazolam pathway.
No canine pregnancy data; rabbit data show fetal effects, so keep the "not proven safe in pregnant animals" caution.
Dogs have dense CB1 receptors; THC signs appear around 0.3–0.5 mg/kg. Non-detect THC removes accumulation and labeling risk.
Practical ceiling from long-term data: 5 mg/kg/day CBD.

Processing and stability

CBDA converts to CBD with heat: half-life about 3.9 hours at 80 °C, 43 minutes at 95 °C, 14 minutes at 110 °C (Wang 2016). Baking destroys the CBDA claim; hot extrusion erodes it; cold-formed soft chews (under 50 °C, no water) preserve it. Wakshlag's cold chew delivered the highest CBDA blood levels of any form tested.
CBD oxidizes with heat, light and air: at room temperature, 95% remains for about 117 days in solution; refrigerated it holds a year. Use low water activity (0.6 or below), opaque pouches, nitrogen flush or oxygen scavenger, mixed tocopherols or rosemary extract, and store at 25 °C or below.
CBN is the oxidation product of THC, not CBD. In a THC-free chew, CBN cannot appear with age; any CBN on the label has to be added isolate.
Test finished chews, not just the input oil: potency for CBD, CBDA, THC, plus homogeneity across chews.

Co-actives with canine evidence

Co-active	Evidence in dogs	Grade	Typical daily amount, 40 lb dog
Alpha-casozepine (Zylkene)	Several small trials, one 2026 placebo-controlled crossover, plus the Flint 2025 blend	B minus	15 mg/kg, about 270 mg
L-theanine (Anxitane)	Two manufacturer studies, weak	C	100 mg twice daily
L-tryptophan	Mixed; one large RCT null	C	10–15 mg/kg
Magnolia + phellodendron	One blinded thunderstorm study	C plus	per label
Melatonin, chamomile, valerian, passion flower	No controlled canine trials	none	—
Glucosamine HCl + chondroitin	One RCT vs carprofen, slower onset; reviews call it conflicting	B minus / C	about 500 mg + 400 mg
UC-II undenatured collagen	Several RCTs, one matching an NSAID on mobility	B	10–40 mg, weight-independent
Green-lipped mussel	One positive RCT vs placebo; others null	B minus	not published
Turmeric (P54FP)	One RCT: vet assessment improved, owner scores not	C	not published
Boswellia	One open-label study, GI side effects in some	C	400 mg per 10 kg
MSM	No canine controlled evidence	none	—
Omega-3 EPA/DHA	Strong diet-level evidence, but effective dose (about 2.7 g/day) is far beyond a chew	A minus at diet level	not reachable in a chew
Probiotics (BL999 for calm; SF68 for GI)	One conference abstract (calm); one null shelter RCT (GI)	C	per label
Pumpkin, flaxseed	No canine evidence; dogs convert flax ALA poorly	none	—

Sources